Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced preclinical results in the development of INM-405 for the treatment of pain. Notably, results from the company’s studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects. InMed suggests that this lack of side effects may position cannabinoid-based compounds as more desirable treatment options than existing systemic pain-relief administration. News of these findings follows the company’s recent filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which marked an important step in InMed’s efforts to protect its intellectual and commercial property.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More